Related Experiment Video
Updated: Jun 3, 2026

Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models
Published on: April 7, 2018
Pancreatic multicenter ultrasound study (PAMUS)
Mirko D'Onofrio1, Emilio Barbi, Christoph F Dietrich
1Department of Radiology, University Hospital G.B. Rossi, University of Verona, Italy. mirko.donofrio@univr.it
Contrast-enhanced ultrasound (CEUS) accurately characterizes pancreatic lesions. This imaging method improves diagnostic confidence for both solid and cystic pancreatic masses, proving valuable in clinical practice.
Area of Science:
- Gastroenterology
- Radiology
- Medical Imaging
Background:
- Pancreatic lesions require accurate characterization for appropriate management.
- Contrast-enhanced ultrasound (CEUS) offers a dynamic imaging modality for assessing organ perfusion.
Purpose of the Study:
- To define the characteristic appearance of pancreatic lesions on CEUS.
- To assess the diagnostic accuracy of CEUS in differentiating benign from malignant pancreatic masses.
Main Methods:
- Retrospective review of 1439 pancreatic lesions across six centers over five years.
- Analysis of lesion size, aspect, and enhancement patterns using CEUS.
- Calculation of sensitivity, specificity, and predictive values; ROC curve analysis for diagnostic performance.
Main Results:
- CEUS accurately characterized solid (87.8% for adenocarcinomas) and cystic (97.1% for cystic tumors) lesions.
- Diagnostic confidence significantly improved with CEUS compared to conventional ultrasound (ROC area 0.877 vs. 0.637).
- High inter-observer agreement was noted for solid and cystic lesions; no side effects reported.
Conclusions:
- CEUS demonstrates high accuracy in characterizing diverse pancreatic lesions.
- CEUS serves as a valuable complementary imaging tool for pancreatic lesion diagnosis.
Related Concept Videos
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Imaging Studies II: Ultrasonography
Chronic Pancreatitis II: Collaborative Care
Assessment:
